JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Axsome Therapeutics Inc

Gesloten

SectorGezondheidszorg

103.02 -3.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

102.01

Max

106.71

Belangrijke statistieken

By Trading Economics

Inkomsten

15M

-59M

Verkoop

2.7M

121M

Winstmarge

-48.914

Werknemers

712

EBITDA

14M

-57M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+68.82% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-529M

4.9B

Vorige openingsprijs

106.26

Vorige sluitingsprijs

103.02

Nieuwssentiment

By Acuity

54%

46%

321 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Axsome Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 21:42 UTC

Winsten
Acquisities, Fusies, Overnames

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug 2025, 21:21 UTC

Winsten
Belangrijke Marktbewegers

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug 2025, 20:45 UTC

Winsten

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug 2025, 23:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 aug 2025, 23:41 UTC

Marktinformatie

Nikkei May Rise on Fed Stimulus Hopes

4 aug 2025, 23:28 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 aug 2025, 23:28 UTC

Marktinformatie

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug 2025, 21:30 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 21:21 UTC

Winsten
Acquisities, Fusies, Overnames

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug 2025, 21:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug 2025, 20:25 UTC

Marktinformatie

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss $938M >RIG

4 aug 2025, 20:25 UTC

Winsten

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug 2025, 20:18 UTC

Winsten

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug 2025, 20:15 UTC

Winsten

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug 2025, 20:14 UTC

Winsten

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug 2025, 20:13 UTC

Winsten

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug 2025, 20:09 UTC

Winsten

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug 2025, 20:06 UTC

Winsten

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug 2025, 20:01 UTC

Winsten

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug 2025, 19:41 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug 2025, 19:28 UTC

Marktinformatie

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug 2025, 19:07 UTC

Marktinformatie

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug 2025, 18:27 UTC

Marktinformatie

Gold Climbs on Rate Cut Speculation -- Market Talk

Peer Vergelijking

Prijswijziging

Axsome Therapeutics Inc Prognose

Koersdoel

By TipRanks

68.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 173.92 USD  68.82%

Hoogste 210 USD

Laagste 148 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Axsome Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

107.24 / 112.29Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

321 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.